Pfizer Inc. and BioNTech SE said Thursday that U.S. regulators have cleared their refreshed COVID-19 shot, giving American providers a strain-matched option just as the fall respiratory season approaches. The Food and Drug Administration signed off on a supplemental license application covering the 2026-2027 version of COMIRNATY, now formulated to target the XFG lineage rather than earlier circulating strains.
The newly authorized shot, branded COMIRNATY XFG, is cleared for adults 65 and older, along with anyone between 5 and 64 who carries an underlying health condition that raises their risk of serious COVID-19 illness. Regulators based their decision on an accumulated evidentiary record spanning clinical trials, laboratory data, and years of real-world use, layered with fresh manufacturing and non-clinical findings. That newer data indicated the reformulated vaccine triggered a robust immune reaction not only against XFG itself but against related descendants circulating this year, including XFG.1.1, NB.1.8.1, PQ.17 and PQ.2.8.1.
Choosing XFG as the season’s target strain follows direction the FDA issued earlier this year identifying it as the composition best suited to U.S. vaccination efforts heading into fall 2026. With sign-off secured, the companies said doses would begin moving to pharmacies, hospitals and clinics nationwide right away, with broad availability expected within days.
COMIRNATY’s mRNA platform, jointly advanced by the two companies, has now been administered in excess of five billion doses worldwide since its introduction, a track record the companies point to as evidence of a consistent safety and effectiveness profile built on continuous pharmacovigilance and manufacturing oversight.
Written By: Sayan Das
Graphics by: Pramit Hazra
